



# OPEN CALL FOR GRANT PROPOSALS

General Conditions

## Adhesion Prevention in women undergoing gynaecological surgery

### Sponsor background

NORDIC Pharma is a global pharmaceutical company particularly involved to further improve women's healthcare. Since Hyalobarrier®'s launch, NORDIC Pharma has been strongly committed to increasing awareness on adhesions to ensure better prevention and help preserve fertility.

### ESGE endorsement

European Society for Gynaecological Endoscopy (ESGE) aims to encourage the exchange of clinical experience, scientific thought and investigation among European gynaecological endoscopists and practitioners in related techniques.

The ESGE encourages research and evaluation of endoscopy related techniques. The recommendation of standards of training in gynaecological endoscopy and related specialties and the cooperation with national and international affiliated societies are also important objectives that ESGE has set.

ESGE is grateful to NORDIC Pharma for this independent research Grant that will support the successful member(s) in conducting research in a field that has very limited funding available.

### Objective and scope of the Grant

This research Grant aims at promoting clinical research and best practice in the management of adhesion prevention in gynaecological surgery to preserve fertility, particularly for patients undergoing high-risk surgery, including:

- Ovarian surgery
- Endometriosis surgery
- Tubal surgery
- Caesarean section surgery
- Myomectomy
- Adhesiolysis
- Oncology surgery
- Uterine curettage and hysteroscopic procedures

Another objective is to evaluate the medico-economic benefits of managing adherence prophylaxis.

Animal research and retrospective analyses on data older than 5 years will not be taken into consideration.

The application for the Grant must be presented by a single project leader.

## Grant Amount

This Grant includes financial assistance amounting to a total of 10,000 euros and the possibility of professional medical writing assistance for English manuscript preparation. This manuscript will be submitted to an international, peer reviewed journal.

The NORDIC Pharma/ESGE Grant Committee may decide to award the total amount of this grant to fund one project or split it between two projects.

This financial contribution will be paid to an organisation (private, public, research, hospital). It is the beneficiary's responsibility to declare the amount received according to local employment and fiscal regulations.

## Eligible Applicants

This Grant is open to European Healthcare Professionals involved in gynaecological surgery either registered or in training.

Only applications that fulfill the eligibility criteria will be considered for the Grant.

## Admissibility Requirements

Each candidate must provide a complete dossier containing the following items:

- A current curriculum vitae (in English) - max 2 sides of A4
- A letter certifying senior staff agreement, where applicable
- A filled-in Grant application form (see template)

Failure to comply with those requirements will lead to the rejection of the application.

## Chosen Applicant's commitments

By submitting this application, the applicant agrees to follow the below rules:

- inform the NORDIC Pharma/ESGE Grant Committee of all other financial resources, either applied for or obtained.
- present the research results at the 2021 ESGE congress, depending on the duration of the project.
- inform NORDIC Pharma/ESGE Grant Committee of the project's progress by means of written interim reports every 6 months.
- inform NORDIC Pharma/ESGE Grant Committee of the final results before external communication.
- declare all support provided by NORDIC Pharma/ESGE in any communication or publication.
- provide a detailed allocation of the total Grant budget.

## Nordic Pharma/ESGE Grant Committee

The NORDIC Pharma/ESGE Grant Committee is composed of:

- Professor Rudy Leon De Wilde (Germany)
- Professor Julio Alvarez Bernardi (Spain)

- Doctor Angelo Hooker (The Netherlands)
- Professor Ying Cheong (UK)
- Professor Attilio Di Spiezio Sardo (Italy)
- Professor Philippe Robert Koninckx (Belgium)
- Professor Per Lundorff (Denmark)
- Professor Leszek Pawelczyk (Poland)
- Professor Markus Wallwiener (Germany)
- Doctor Laurence Saya (on behalf of NORDIC Pharma)

In the event that the project is submitted by a person working together with one member of this committee, the member of the committee will not participate in the discussion regarding this project.

The eligibility and the awards are determined at the sole discretion of the NORDIC Pharma/ESGE Grant Committee. All decisions made by the NORDIC Pharma/ESGE Grant Committee are final and are not subject to appeal. No reason for failure to award will be given.

#### Submission

- The applications must be sent in English by email to **centraloffice@esge.org**
- All applications must be received by end of June 2020. A reception of email acts as proof of reception.

### Awarding the Grant

- The NORDIC Pharma/ESGE Grant Committee will select the beneficiary(.ies) according to the quality and originality of the research proposal.
- The beneficiary(.ies) will be informed by a NORDIC Pharma/ESGE Grant Committee representative in July 2020 at the latest. An agreement will be sent to the person in charge of the project. This document will specify the amount and the terms of payment as well as the conditions that need to be fulfilled to receive the Grant (expenses proofs, activity reports and evaluation). The notification letters will be sent by e-mail to "the follow-up address" indicated in the file.
- The selected projects will be published on the ESGE website.
- The projects will be awarded during the next ESGE congress.

### Award deferral

In the event there is an insufficient number of applicants, the committee and the organiser reserve the right to either defer the final application date or defer this call for Grant to a later date altogether.

### Data protection

All personal data (such as names, addresses, CVs, etc.) will be processed in accordance with EU Regulation 2016/679 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data.

Unless marked as optional, the applicant's replies to the questions in the application form are necessary to evaluate and further process the Grant application in accordance with the specifications of the Call for proposals. Personal data will be processed solely for that purpose by the Grant Committee.

Personal data may be transferred on a need to know basis to third parties involved in the evaluation of applications or in the Grant management procedure, without prejudice of transfer to the bodies in charge of monitoring and inspection tasks in accordance with European Union law.

The applicant has the right of access to, and to rectify, the data concerning him or her. For any question relating to these data, please contact NORDIC Pharma at [dataprivacy@nordicpharma.com](mailto:dataprivacy@nordicpharma.com).

## Submission of the Grant application

Proposals must be received in accordance with the admissibility requirements section.

No modification to the application are allowed once the deadline for submission has elapsed. However, if there is a need to clarify certain aspects or for the correction of clerical mistakes, the Grant Committee may contact the applicant for this purpose during the evaluation process.

Applicants will be informed in writing about the results of the selection process.

## Annexes

Grant application form